Takeda-partnered Finch Therapeutics grabs $36M and looks to leapfrog the pack in microbiome R&D
Close to a year after Seres declared that it had jumped back on track after a troubling setback with its lead microbiome drug for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
